SCHEMBL5117646

SCHEMBL5117646

CCCN1C(=O)C(=NNC(=O)Nc2ccc(F)cc2)c2cc(SCCCc3ccc(C(=O)O)cc3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
KDR P35968 1/20 0.39
RXRA P19793 2/20 0.36
CCR3 P51677 1/20 0.34
ALOX5 P09917 1/20 0.33
PARK7 Q99497 1/20 0.33
F9 P00740 1/20 0.33
SSTR5 P35346 1/20 0.33
AGTR1 P30556 1/20 0.33
AGTR2 P50052 1/20 0.33
PTPN7 P35236 1/20 0.33
RAB9A P51151 1/20 0.33
PTPN12 Q05209 1/20 0.33
GPR35 Q9HC97 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTPN22 Q9Y2R2 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125414 1.00 CA12 (0.39) CA12CA1CA2CA9KDR
SCHEMBL14287346 1.00 CA12 (0.39) CA12CA1CA2CA9KDR
SCHEMBL14287368 0.96 CA12 (0.35) CA12CA1CA2CA9KDR
SCHEMBL5110445 0.96 CA12 (0.35) CA12CA1CA2CA9KDR
SCHEMBL5110441 0.96 CA12 (0.35) CA12CA1CA2CA9KDR
SCHEMBL5113928 0.95 CA12 (0.40) CA12CA1CA2CA9KDR
SCHEMBL14287366 0.95 CA12 (0.40) CA12CA1CA2CA9KDR
SCHEMBL5113932 0.95 CA12 (0.40) CA12CA1CA2CA9KDR
SCHEMBL5124208 0.95 PLK1 (0.35) CA12CA1CA2CA9KDR
SCHEMBL14287370 0.95 PLK1 (0.35) CA12CA1CA2CA9KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-03 US claimed
EP-1828124-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development (FR) 2007-09-05 EP claimed
WO-2006063863-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-06-22 WO claimed
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-03 US disclosed
EP-1828124-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development (FR) 2007-09-05 EP disclosed
WO-2006063863-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA CA12 4873/4885CA1 4882/4885CA2 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.